For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Nootropic / Cognitive

Cerebrolysin

Also known as: FPF-1070

Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States.

Where to buy · live market data

Who's worth your money for Cerebrolysin

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (82) of 4 scored sellers

$0.88/mg

$52.50 · 60mg

no COAs yet
Buy code MERIT · 15% off

Best value

Lowest $/mg among scored sellers

$0.83/mg

$49.99 · 60mg

no COAs yet

Average price

$1.25/mg

Sellers

18

45-day trend

+21.2%

13 of 18 sellers have a current price· 8 stale hidden· 1 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Cerebrolysin

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Cerebrolysin

CAS

12656-61-0

Molecular formula

Typical dose range

5–30 mL IV daily for 10–20 day courses; lower end (5–10 mL) used for cognitive applications

Half-life

~2.5–6 hours (plasma); CSF half-life ~12–18 hours; therapeutic effects persist 48–96 hours

Research depth

20 citations indexed for Cerebrolysin

All research on Cerebrolysin →

Study · 2026

Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report

Despite high recanalization rates with mechanical thrombectomy (MT), large-vessel occlusion stroke results in death or dependency in over half of patients. Cerebrolysin, a multimodal neuropeptide preparation, may attenuate ischemia-reperfusion injury and support early neurorehabilitation.

case-report · 2026

Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report

Basilar artery occlusion (BAO) is an uncommon yet devastating cause of posterior circulation stroke, frequently resulting in severe disability or death despite successful reperfusion.

Study · 2026

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability

Cerebrolysin has a salutary effect on impaired cerebral endothelial cell (CEC) permeability. Using an in vitro endothelial permeability assay, the present study tested the hypothesis that exosomes released by Cerebrolysin-treated CECs (Cerebro-Exos) have a robust therapeutic effect on dysfunctional CECs.

case-report · 2026

Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report

Post-stroke aphasia is a debilitating condition affecting approximately one-third of stroke survivors, profoundly impairing communication, social participation, and quality of life.

Study · 2026

ABSTRACT NUMBER: ESOC2026A2077 NEUROD AND NNT1 AS PREDICTORS OF THE OUTCOMES IN ACUTE ISCHEMIC STROKE PATIENTS UNDERGOING MECHANICAL THROMBECTOMY

Study · 2026

ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT